Transient and Efficient Vascular Permeability Window for Adjuvant Drug Delivery Triggered by Microbeam Radiation.
Chicken Chorioallantoic Membrane (CAM)
U-87 Glioblastoma
drug delivery system
microbeam radiation therapy (MRT)
vascular permeability
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
27 04 2021
27 04 2021
Historique:
received:
31
03
2021
revised:
23
04
2021
accepted:
24
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
Microbeam Radiation Therapy (MRT) induces a transient vascular permeability window, which offers a novel drug-delivery system for the preferential accumulation of therapeutic compounds in tumors. MRT is a preclinical cancer treatment modality that spatially fractionates synchrotron X-rays into micrometer-wide planar microbeams which can induce transient vascular permeability, especially in the immature tumor vessels, without compromising vascular perfusion. Here, we characterized this phenomenon using Chicken Chorioallantoic Membrane (CAM) and demonstrated its therapeutic potential in human glioblastoma xenografts in mice. the developing CAM was exposed to planar-microbeams of 75 Gy peak dose with Synchrotron X-rays. Similarly, mice harboring human glioblastoma xenografts were exposed to peak microbeam doses of 150 Gy, followed by treatment with Cisplatin. Tumor progression was documented by Magnetic Resonance Imaging (MRI) and caliper measurements. CAM exposed to MRT exhibited vascular permeability, beginning 15 min post-irradiation, reaching its peak from 45 min to 2 h, and ending by 4 h. We have deemed this period the "permeability window". Morphological analysis showed partially fragmented endothelial walls as the cause of the increased transport of FITC-Dextran into the surrounding tissue and the extravasation of 100 nm microspheres (representing the upper range of nanoparticles). In the human glioblastoma xenografts, MRI measurements showed that the combined treatment dramatically reduced the tumor size by 2.75-fold and 5.25-fold, respectively, compared to MRT or Cisplatin alone. MRT provides a novel mechanism for drug delivery by increasing vascular transpermeability while preserving vessel integrity. This permeability window increases the therapeutic index of currently available chemotherapeutics and could be combined with other therapeutic agents such as Nanoparticles/Antibodies/etc.
Sections du résumé
BACKGROUND
Microbeam Radiation Therapy (MRT) induces a transient vascular permeability window, which offers a novel drug-delivery system for the preferential accumulation of therapeutic compounds in tumors. MRT is a preclinical cancer treatment modality that spatially fractionates synchrotron X-rays into micrometer-wide planar microbeams which can induce transient vascular permeability, especially in the immature tumor vessels, without compromising vascular perfusion. Here, we characterized this phenomenon using Chicken Chorioallantoic Membrane (CAM) and demonstrated its therapeutic potential in human glioblastoma xenografts in mice.
METHODS
the developing CAM was exposed to planar-microbeams of 75 Gy peak dose with Synchrotron X-rays. Similarly, mice harboring human glioblastoma xenografts were exposed to peak microbeam doses of 150 Gy, followed by treatment with Cisplatin. Tumor progression was documented by Magnetic Resonance Imaging (MRI) and caliper measurements.
RESULTS
CAM exposed to MRT exhibited vascular permeability, beginning 15 min post-irradiation, reaching its peak from 45 min to 2 h, and ending by 4 h. We have deemed this period the "permeability window". Morphological analysis showed partially fragmented endothelial walls as the cause of the increased transport of FITC-Dextran into the surrounding tissue and the extravasation of 100 nm microspheres (representing the upper range of nanoparticles). In the human glioblastoma xenografts, MRI measurements showed that the combined treatment dramatically reduced the tumor size by 2.75-fold and 5.25-fold, respectively, compared to MRT or Cisplatin alone.
CONCLUSIONS
MRT provides a novel mechanism for drug delivery by increasing vascular transpermeability while preserving vessel integrity. This permeability window increases the therapeutic index of currently available chemotherapeutics and could be combined with other therapeutic agents such as Nanoparticles/Antibodies/etc.
Identifiants
pubmed: 33925455
pii: cancers13092103
doi: 10.3390/cancers13092103
pmc: PMC8123803
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Swiss National Science Foundation
ID : 31003A_176038
Pays : Switzerland
Organisme : Swiss Cancer League
ID : KFS-4281-08-2017
Organisme : Bernische Krebsliga
ID : 190
Références
J Control Release. 2013 Apr 28;167(2):130-7
pubmed: 23391444
Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):1126-1136
pubmed: 31461675
Circ Res. 2000 Feb 18;86(3):286-92
pubmed: 10679480
Neuro Oncol. 2002 Jan;4(1):26-38
pubmed: 11772430
Am J Cancer Res. 2018 Aug 01;8(8):1642-1660
pubmed: 30210932
Br J Cancer. 1993 May;67(5):975-80
pubmed: 8494731
Int J Exp Pathol. 2010 Dec;91(6):495-9
pubmed: 20804540
Anat Embryol (Berl). 2000 Nov;202(5):347-57
pubmed: 11089926
FASEB J. 2008 Jan;22(1):276-84
pubmed: 17761521
Curr Pharm Biotechnol. 2000 Jul;1(1):73-82
pubmed: 11467363
Annu Rev Pharmacol Toxicol. 2015;55:613-31
pubmed: 25340933
Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1503-12
pubmed: 20932689
J Control Release. 2000 Mar 1;65(1-2):271-84
pubmed: 10699287
Front Oncol. 2013 Aug 15;3:211
pubmed: 23967403
Expert Opin Drug Metab Toxicol. 2021 Feb 10;:1-22
pubmed: 33565346
Cancer Chemother Pharmacol. 2010 Apr;65(5):817-24
pubmed: 19662415
Cell Mol Biol (Noisy-le-grand). 2001 May;47(3):485-93
pubmed: 11441956
Sci Rep. 2019 Apr 4;9(1):5632
pubmed: 30948731
Med Phys. 2013 Jul;40(7):072902
pubmed: 23822453
Radiat Res. 2012 Jun;177(6):804-12
pubmed: 22607585
Int J Mol Sci. 2019 Dec 31;21(1):
pubmed: 31906108
J Clin Oncol. 2013 Jun 10;31(17):2205-18
pubmed: 23669226
Ultrasound Med Biol. 2020 Jun;46(6):1296-1325
pubmed: 32165014
J Am Chem Soc. 2014 Aug 20;136(33):11748-56
pubmed: 25078892
J Biol Chem. 1990 Jun 25;265(18):10681-5
pubmed: 2162358
Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1522-32
pubmed: 21740994
J Control Release. 2015 Mar 10;201:78-89
pubmed: 25526702
Med Phys. 2003 Apr;30(4):583-9
pubmed: 12722810
Bioorg Med Chem. 2009 Apr 15;17(8):2950-62
pubmed: 19299149
Cancers (Basel). 2020 Feb 25;12(3):
pubmed: 32106397
Rev Sci Instrum. 2009 Jul;80(7):074301
pubmed: 19655968
Sci Rep. 2016 Sep 19;6:33601
pubmed: 27640676
Phys Med Biol. 2008 Feb 21;53(4):861-78
pubmed: 18263945
Clin Cancer Res. 2006 Sep 1;12(17):5018-22
pubmed: 16951216
Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8783-7
pubmed: 7568017
Dev Med Child Neurol. 2007 Aug;49(8):577-81
pubmed: 17635201
Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1519-27
pubmed: 16580502
Nanomedicine. 2020 Jun;26:102175
pubmed: 32151749
J Synchrotron Radiat. 2012 Jul;19(Pt 4):478-82
pubmed: 22713877
Nat Commun. 2013;4:2516
pubmed: 24084631
Adv Drug Deliv Rev. 2012 Jan;64(1):53-68
pubmed: 21983328
Br J Radiol. 2006 Jan;79(937):71-5
pubmed: 16421408
J Clin Oncol. 1996 Oct;14(10):2653-65
pubmed: 8874324
Adv Mater. 2017 Oct;29(37):
pubmed: 28752600
Mol Cancer Ther. 2009 Jan;8(1):10-6
pubmed: 19139108
Nat Med. 2004 Feb;10(2):145-7
pubmed: 14745444
Phys Med Biol. 2008 Jul 7;53(13):3609-22
pubmed: 18560052
Jpn J Clin Oncol. 2009 Nov;39(11):756-66
pubmed: 19596662
Cancer Res. 2007 Mar 15;67(6):2729-35
pubmed: 17363594
Cells Tissues Organs. 2021 Mar 29;:1-16
pubmed: 33780951
J Control Release. 2016 Dec 10;243:172-181
pubmed: 27744037
Pharm Res. 2011 Aug;28(8):1819-30
pubmed: 21213021
Nat Rev Neurol. 2016 Aug;12(8):439-54
pubmed: 27364743
Mech Dev. 2016 Aug;141:70-77
pubmed: 27178379
Int J Cancer. 1998 Nov 23;78(5):654-60
pubmed: 9808538
Acta Neurochir (Wien). 1995;136(1-2):82-6; discussion 86-7
pubmed: 8748832
Sci Rep. 2018 Aug 13;8(1):12044
pubmed: 30104646
Int J Radiat Oncol Biol Phys. 2018 Jul 1;101(3):680-689
pubmed: 29559293
Adv Drug Deliv Rev. 2017 Sep 15;119:44-60
pubmed: 28697952